IL10 and melanoma: Finally, in this work, to identify new biomarkers that could be useful to predict response to anti-PD-1 drugs, we examined mRNA expression levels of a panel of pro- and anti-inflammatory cytokines in PBMCs from melanoma patients before first dose of nivolumab treatment, including IL-10, IL-12 and IL-4 and IFN-γ.